Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Healthcare | Drugs - Generic | USA
financial highlights | statements
Index- P/E- EPS (ttm)-4.72 Insider Own0.60% Shs Outstand37.20M Perf Week-6.67%
Market Cap640.58M Forward P/E- EPS next Y-3.17 Insider Trans-13.89% Shs Float36.37M Perf Month-6.57%
Income-170.20M PEG- EPS next Q-1.21 Inst Own- Short Float32.34% Perf Quarter-36.50%
Sales6.30M P/S101.68 EPS this Y-46.50% Inst Trans0.70% Short Ratio19.71 Perf Half Y-29.71%
Book/sh4.92 P/B3.50 EPS next Y32.60% ROA-43.90% Target Price38.64 Perf Year-25.62%
Cash/sh9.15 P/C1.88 EPS next 5Y- ROE-80.80% 52W Range17.26 - 29.10 Perf YTD-31.23%
Dividend- P/FCF- EPS past 5Y-32.60% ROI-30.90% 52W High-40.82% Beta0.69
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin42.50% 52W Low-0.23% ATR1.09
Employees251 Current Ratio12.90 Sales Q/Q- Oper. Margin- RSI (14)36.64 Volatility9.51% 5.82%
OptionableYes Debt/Eq0.86 EPS Q/Q-28.30% Profit Margin- Rel Volume3.66 Prev Close18.94
ShortableYes LT Debt/Eq0.80 EarningsNov 05 AMC Payout- Avg Volume596.68K Price17.22
Recom1.70 SMA20-7.14% SMA50-15.33% SMA200-28.22% Volume2,078,490 Change-9.08%
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
Oct-22-18 07:30AM  Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting GlobeNewswire -9.08%
Oct-16-18 08:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy New Research Emphasizes Economic Growth GlobeNewswire +6.23%
Oct-05-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-10-18 09:00AM  Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology GlobeNewswire
Sep-07-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-18 04:30PM  Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference GlobeNewswire +5.04%
Aug-20-18 05:23PM  Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium GlobeNewswire
Aug-17-18 08:00AM  Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-10-18 06:19AM  Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass. American City Business Journals
Aug-07-18 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:30PM  Flexion Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-30-18 04:30PM  Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE -5.97%
Jul-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-21-18 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Second Year in a Row GlobeNewswire
Jun-19-18 07:15AM  Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-13-18 09:00AM  Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) PR Newswire
Jun-01-18 05:13PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
May-10-18 03:46AM  Edited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:37PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-07-18 07:30AM  Flexion Therapeutics Names David Arkowitz as Chief Financial Officer GlobeNewswire
May-04-18 07:30AM  Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS GlobeNewswire
May-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-30-18 04:30PM  Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-29-18 09:00AM  Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress GlobeNewswire
Apr-26-18 07:30AM  Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress GlobeNewswire +5.52%
Apr-24-18 04:30PM  Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018 GlobeNewswire
Apr-18-18 04:20PM  Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery GlobeNewswire
Apr-06-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:38AM  Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump Zacks
Apr-05-18 07:55AM  Detailed Research: Economic Perspectives on The Habit Restaurants, MUELLER WATER PRODUCTS, The Carlyle Group, Flexion Therapeutics, Hexcel, and Adesto Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.25%
Mar-19-18 09:00AM  Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 06:10PM  Edited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
04:15PM  Why A Key Drug Launch Wasn't Enough To Help This Biotech Stock Investor's Business Daily
Mar-08-18 05:05PM  Flexion Therapeutics reports 4Q loss Associated Press
04:01PM  Flexion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:00PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 09:00AM  Flexion Therapeutics to Present at the Cowen 38th Annual Health Care Conference GlobeNewswire
Mar-06-18 07:30AM  Flexion Therapeutics Presents Clinical Data at AAOS 2018 Annual Meeting and the American Pain Society Annual Scientific Meeting GlobeNewswire
Mar-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-28-18 09:00AM  Flexion Therapeutics to Present at the 39th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-26-18 04:30PM  Flexion Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 8, 2018 GlobeNewswire
Feb-14-18 04:30PM  Flexion Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Feb-08-18 07:55AM  New Research: Key Drivers of Growth for Radian Group, Flexion Therapeutics, Andeavor, Haverty Furniture Companies, Ares Capital, and Sempra Energy Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-02-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-08-18 07:30AM  Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-29-17 09:00PM  3 Biotechs Launching Their First Commercial Drugs in 2018 Motley Fool
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Dec-18-17 04:05PM  Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Osteoarthritis of the Shoulder and Hip GlobeNewswire
Dec-13-17 04:05PM  Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee GlobeNewswire
Dec-11-17 04:05PM  Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer GlobeNewswire
Dec-10-17 07:16PM  2018 Is a Critical Year for These 3 Small Commercial-Stage Biotech Stocks Motley Fool
Dec-07-17 04:35PM  Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in Bilateral Osteoarthritis of the Knee GlobeNewswire
Dec-06-17 04:30PM  Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Dec-04-17 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-17 05:01PM  Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market Zacks
Nov-29-17 03:00AM  Stocks To Watch: Flexion Therapeutics Sees RS Rating Jump To 83 Investor's Business Daily
Nov-28-17 04:05PM  Flexion Therapeutics to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference GlobeNewswire
11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
07:14AM  This Small-Cap Biotech Stock Is Onto Something Big Motley Fool
Nov-27-17 08:00AM  Today's Research Reports on Stocks to Watch: Flexion Therapeutics and Teva Pharmaceutical ACCESSWIRE -7.03%
Nov-20-17 07:30AM  Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Nov-17-17 09:00AM  Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe GlobeNewswire
Nov-08-17 08:41PM  Edited Transcript of FLXN earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-17 01:23PM  Is There Now An Opportunity In Flexion Therapeutics Inc (FLXN)? Simply Wall St.
Nov-06-17 05:07PM  Flexion Therapeutics reports 3Q loss Associated Press
04:05PM  Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
03:00AM  Flexion Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Nov-02-17 04:05PM  Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting GlobeNewswire
Oct-30-17 04:05PM  Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017 GlobeNewswire
Oct-25-17 01:18PM  Stocks on My Radar on This Selling TheStreet.com -5.68%
Oct-17-17 01:55PM  Applied Optoelectronics, Helios And Matheson Among The Top Stocks With Short Sellers Benzinga
Oct-15-17 05:00PM  Flexion's Latest FDA Approval Reignites Takeover Chatter TheStreet.com
Oct-13-17 01:15AM  A New FDA Approval Sends Small Cap Flexion Soaring Motley Fool
Oct-11-17 05:55PM  Flexion Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
09:23AM  Flexion Shares Lower After Proposed Stock Offering -- Biotech Movers TheStreet.com
Oct-10-17 04:05PM  Flexion Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-09-17 04:19PM  Flexion CEO: Absolutely thinking about exploring additional uses for new non-opioid drug CNBC -5.65%
02:33PM  Flexion CEO on non-opioid knee pain treatment CNBC Videos
10:15AM  Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up Zacks
09:21AM  Flexion Shares Continue Rise After FDA Approval -- Biotech Movers TheStreet.com
09:00AM  Flexion Can Double Now That FDA Has Approved Zilretta Forbes
08:51AM  Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher Zacks
07:00AM  Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) PR Newswire
03:00AM  Flexion Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily
Oct-07-17 10:20AM  Flexion shares surge on FDA approval for its non-opioid knee pain medication MarketWatch
Oct-06-17 04:30PM  Flexion's knee pain drug gets FDA nod, shares hit life high Reuters +10.36%
04:26PM  This Biotech Could Reap North Of $1 Billion For Painkiller Investor's Business Daily
04:12PM  Edited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents
03:45PM  Flexion Secures FDA Nod for Osteoarthritis Knee Pain Treatment, Shares Skyrocket TheStreet.com
03:42PM  Flexion soars on FDA drug approval CNBC Videos
03:25PM  Burlington biotech Flexion eyes expansion after FDA approves pain drug American City Business Journals
03:23PM  Flexion shares surge 18% on news of FDA approval for non-opioid knee pain injection MarketWatch
03:07PM  Flexion's knee pain drug gets FDA nod Reuters
03:00PM  Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain GlobeNewswire
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arkowitz DavidChief Financial OfficerAug 09Buy23.424,00093,68044,250Aug 10 12:56 PM
Clayman Michael D.President and CEOAug 09Buy22.3310,000223,30075,282Aug 10 09:13 AM
Bodick NeilChief Scientific OfficerJul 03Sale25.0016,492412,30062,307Jul 03 04:07 PM
Bodick NeilChief Scientific OfficerJul 02Sale25.1033,508841,19278,799Jul 03 04:07 PM
Bodick NeilChief Scientific OfficerMay 11Option Exercise0.1637,7026,130112,307May 11 04:07 PM
Bodick NeilChief Scientific OfficerNov 21Buy24.391,70041,45764,605Nov 22 05:28 PM
Bodick NeilChief Scientific OfficerNov 21Buy24.661,00024,6561,000Nov 22 05:28 PM
Clayman Michael D.President and CEONov 08Buy23.605,000118,00035,395Nov 09 09:13 AM
open in yahoo | open in reuters | open in google